| | Gene | Cases | Controls | OR crude (CI 95%)* | OR adjusted (CI 95%)+ |
| | All cancers | | | | |
| | CYP1A1 | | | | |
| | No mutated | | | 1.00 | 1.00 | | Mutated | | | 0.72
(0.10–5.28) | 1.68
(0.18–15.70) |
| | mEH
(139) | | | | |
| | His/His | | | 1.00 | 1.00 | | His/Arg | | | 0.95
(0.52–1.75) | 0.81
(0.38–1.71) | | Arg/arg | | | 4.30
(0.46–40.07) | 4.45
(0.39–50.45) |
| | GSTM1 | | | | |
| | Present | | | 1.00 | 1.00 | | Absent | | | 1.16
(0.73–1.99) | 1.25
(0.65–2.40) |
| | Oral cancer | | | | |
| | CYP1A1 | | | | |
| | No mutated | 53 | 64
(97%) | 1.00 | 1.00 | | Mutated | 0 | 2
(3%) | — | — |
| | mEH
(139)
| | | | |
| | His/His | 39
(73,6%) | 88
(67,7%) | 1.00 | 1.00 | | His/Arg | 12
(22,6%) | 41
(31,5%) | 0.74
(0.34–1.58) | 0.54
(0.21–1.41) | | Arg/arg | 2
(3,8%) | 1
(0,8%) | 3.44
(0.29–40.16) | 4.32
(0.32–58.63) |
| | GSTM1 | | | | |
| | Present | 26
(49,1%) | 68
(52,3%) | 1.00 | 1.00 | | Absent | 27
(50,9%) | 62
(47,7%) | 1.14
(0.60–2.19) | 1.20
(0.56–2.18) |
| | Pharyngeal cancer | | | | |
| | CYP1A1 | | | | |
| | No mutated | 37
(94,9%) | 64
(97%) | 1.00 | 1.00 | | Mutated | 2
(5,1%) | 2
(3%) | 1.74
(0.23–12.92) | 4.06
(0.43–38.24) |
| | mEH
(139) | | | | |
| | His/His | 24
(61,5%) | 88
(67,7%) | 1.00 | 1.00 | | His/Arg | 13
(33,3%) | 41
(31,5%) | 1.27
(0.58–2.80) | 1.07
(0.42–2.71) | | Arg/arg | 2
(5,2%) | 1
(0,8%) | 5.58
(0.47–66.10) | 5.74
(0.34–97.71) |
| | GSTM1 | | | | |
| | Present | 19
(48,7%) | 68
(52,3%) | 1.00 | 1.00 | | Absent | 20
(51,3%) | 62
(47,7%) | 1.20
(0.58–2.48) | 1.44
(0.61–3.37) |
|
|
